The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 1940-1946

  Fung, James ^a   Lai, Ching Lung ^a   Tanaka, Yasuhito ^b   Mizokami, Masashi ^a   Yuen, John ^a   Wong, Danny Ka Ho ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEROCONVERSION;

ADULT; CHINA; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; YOUNG ADULT;

EID: 68349128691     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.200     Document Type: Article

References (26)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
3. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
4. Liaw Y, Leung N, Chang T et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
5. Leung N, Lai C, Chang T et al. Extended lamivudine treatment in patients with chronic hepatitis Benhances hepatitis Be antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
6. Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-8.
7. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
8. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis Be antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
9. Song BC, Suh DJ, Lee HC et al. Hepatitis Be antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32 (4 Part 1): 803-6.
10. Byun KS, Kwon OS, Kim JH et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005;20:1838-42.
11. Alexander G, Baba CS, Chetri K et al. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol 2005;5:29.
12. Chien RN, Yeh CT, Tsai SL et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
13. Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-4.
14. Sugauchi F, Orito E, Ichida T et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;124:925-32.
15. Tanaka Y, Mukaide M, Orito E et al. Specific mutations inenhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 2006;45:646-53.
16. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
17. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis Be antigen seroconversion and the development of cirrhosisrelated complications. Hepatology 2001;34:139-45.
18. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
19. Lee KM, Cho SW, Kim SW et al. Effect of virological response on posttreatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-12.
20. Huang YH, Wu JC, Chang TT et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis Be antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003;10:277-84.
21. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003;39:614-9.
22. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-62.
23. Liu CJ, Huang WL, Chen PJ et al. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004;10:3574-8.
24. Lok A, Lai C, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
25. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
26. Fung J, Yuen MF, Yuen JC et al. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case -control study. Aliment Pharmacol Ther 2007;26:377-82.